HALO News and Press, Halozyme Therapeutics Inc. From 02/28/20

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in Boston . Dr. Helen Torley , president and chief executi...

Halozyme Therapeutics, Inc. (HALO) Q4 2019 Earnings Conference Call February 24, 2020 04:30 p.m. ET Company Representatives Helen Torley - President, Chief Executive Officer Al Kildani - Vice President of Investor Relations and Corporate Communications Conference Call Participan...

SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member of the Roche Group, for the fixed-dose combination of pertuzu...

Image source: The Motley Fool. Halozyme Therapeutics Inc   (NASDAQ: HALO) Q4 2019 Earnings Call Feb 24, 2020 , 4:30 p.m. ET Operator Continue reading

Halozyme Therapeutics (NASDAQ: HALO ) has dipped 1.5% postmarket after posting its Q4 report, where revenues and profits trailed expectations though the company reiterated strong guidance and upcoming sustained profitability. More news on: Halozyme Therapeutics, Inc., Healthcare stocks n...

Halozyme Therapeutics (NASDAQ: HALO ): Q4 GAAP EPS of -$0.24 misses by $0.06 . Revenue of $53.68M (-10.9% Y/Y) misses by $2.01M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its recent corporate activities and outlook. "I am pleased to report 2020 i...

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020 . Ms. Sun will succeed Laurie Stelzer , who has resigned to pursue a...

SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, w...